Additional file 1: Table S1. Clinical features and results of indicative biomarkers in the DLB group. Table S2. CSF NfL, GFAP, and AD core biomarker values across diagnostic groups. Table S3. Plasma NfL, GFAP, and p-tau181 values across diagnostic groups. Table S4. CSF and plasma NfL, GFAP, and p-tau181 across FTD phenotypic continuum. Table S5. CSF and plasma NfL, GFAP, and p-tau181 in genetic and sporadic FTD. Fig. S1. Plasma NfL levels in the SNAP group according to the clinical presentation. Fig. S2. Accuracy of plasma NfL, p-tau181, and GFAP in discriminating between healthy controls and disease groups. Fig. S3. CSF and plasma diagnostic accuracies for each biomarker across disease groups. Fig. S4. Plasma biomarker levels in CBS and DLB according to the amyloid status (left) and ROC curves after excluding A+ cases in non-AD disease groups (right).